相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
L. H. Cavallari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing
Nitin Roper et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic
Paul B. Shaw et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2010)
Role of warfarin pharmacogenetic testing in clinical practice
Guang-Ming Tan et al.
PHARMACOGENOMICS (2010)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients
Masako Ohno et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Validation of Clinical Testing for Warfarin Sensitivity Comparison of CYP2C9-VKORC1 Genotyping Assays and Warfarin-Dosing Algorithms
Michael R. Langley et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients
Sheng-Wen Huang et al.
PHARMACOGENETICS AND GENOMICS (2009)
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
Shinya Goto et al.
AMERICAN HEART JOURNAL (2008)
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Danxin Wang et al.
BLOOD (2008)
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes
M-S Wen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans
H. Schelleman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
G. Oner Ozgon et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population:: comparison with other equations
Alan H. B. Wu et al.
PHARMACOGENOMICS (2008)
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients
Liyan Miao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
Jeffrey L. Anderson et al.
CIRCULATION (2007)
Estimation of warfarin maintenance dose based on VKORCI (-1639 G>A) and CYP2C9 genotypes
Yusheng Zhu et al.
CLINICAL CHEMISTRY (2007)
Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
Elaine M. Hylek et al.
CIRCULATION (2007)
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose:: a prospective study
John F. Carlquist et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2006)
A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P4502C9
Lai-San Tham et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen
EA Sconce et al.
BLOOD (2005)
Warfarin maintenance dosing patterns in clinical practice - Implications for safer anticoagulation in the elderly population
D Garcia et al.
CHEST (2005)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
分享论文
